Work

A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.11075

Authors: Kathleen N. Moore, Anna M. Varghese, David Michael Hyman, Sophie Callies, Ji Lin, Volker Wacheck, Shubham Pant, Todd Michael Bauer, Johanna C. Bendell

Institutions: University of Oklahoma Health Sciences Center, Memorial Sloan Kettering Cancer Center, Eli Lilly (United Kingdom), Eli Lilly (United States), Sarah Cannon, Tennessee Oncology

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2598882746

Cites:

Cited by: 8

Related to: 10